Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease

Kamble, Rammurti T.; Tin-U, C K; Carrum, George

doi:10.1038/sj.bmt.1705376

Cited by 13 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, there has been one report published regarding successful autologous peripheral blood HPC collection and transplantation for hematologic malignancy in a patient with Hb SC disease 8 . In this case, reported by Kamble and coworkers, 8 RBC exchange was performed prior to HPC mobilization. Their patient received a 10 µg per kg dose of filgrastim with subsequent HPC harvesting via peripheral blood leukapheresis.…”

Section: Discussionmentioning

confidence: 93%

Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease

2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease

2008

View full text Add to dashboard Cite

show abstract

“…Five individuals experienced pain severe enough to require hospitalization and narcotic therapy [1, 4, 5]. One individual received G-CSF on two occasions; he experienced a VOC requiring hospitalization with prophylactic doses of G-CSF to prevent CIN, but tolerated subsequent G-CSF for autologous HSC mobilization without complications [4]. In total, 7 of the 11 individuals required hospitalization [1–5], while 4 others experienced no complications [5–7].…”

Section: Case Reports Of G-csf Use In Scdmentioning

confidence: 99%

“…Two others received simple red cell transfusion therapy, and one had back and extremity pain similar to prior VOC. In total, 3 of 4 patients in the red cell transfusion group [4–7], and 2 of 8 patients in the no transfusion group [1–5] were free of adverse events (again, one patient received G-CSF on two occasions). However, there was no threshold HbS under which VOC was prevented, as a patient with a HbS as low as 14.4% experienced VOC requiring hospitalization, and another patient with a HbS level of 75% did not have complications (Table I).…”

Section: Attempted Strategies To Reduce Scd-related G-csf Complicatiomentioning

confidence: 99%

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Fitzhugh

Hsieh

Bolan³

et al. 2009

Cytotherapy

114

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) is used commonly in an attempt to reduce the duration of neutropenia and hospitalization in patients undergoing chemotherapy and to obtain hematopoietic stem cells (HSC) for transplantation applications. Despite the relative safety of administration of G-CSF in most individuals, including subjects with sickle cell trait, severe and life-threatening complications have been reported when used in individuals with sickle cell disease (SCD), including those who were asymptomatic and undiagnosed prior. The administration of G-CSF has now been reported in a total of 11 individuals with SCD. Seven developed severe adverse events including vaso-occlusive episodes, acute chest syndrome, multi-organ system failure, and death. Precautions including minimizing the peak white blood cell count, dividing or reducing the G-CSF dose, and red blood cell transfusions to reduce HbS levels have been employed with no consistent benefit. These reported data indicate that administration of G-CSF in individuals with SCD should be undertaken only in the absence of alternatives, and after full disclosure of the risks involved. Unless further data demonstrate safety, routine usage of G-CSF in individuals with SCD should be avoided.

show abstract

“…This is even more important in the current era where colony stimulating factors are used for peripheral blood stem cells (PBSC) mobilization in hematopoietic stem cell transplant donors and in patients with sickle cell anemia requiring myelosuppressive chemotherapy for other neoplasms where growth factor support may be needed [11, 19]. …”

Section: Discussionmentioning

confidence: 99%

“…In patients developing significant leucocytosis and crises, interventions aiming at reducing the white blood cell counts may be worth considering [12]. Split dose schedule schedules and exchange transfusions to reduce the levels of HbS have also been shown to be effective in isolated cases [19–22]. It would also be advisable that if after consideration of risks and benefits, the use of filgrastim and pegfilgrastim is indicated, that it be done in centers equipped with dealing with patients with sickle cell anemia.…”

Section: Discussionmentioning

confidence: 99%

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia

Kasi

Patnaik

Peethambaram

2013

Case Reports in Hematology

View full text Add to dashboard Cite

Pegfilgrastim (Neulasta) is a recombinant filgrastim (human granulocyte colony-stimulating factor (G-CSF)) attached to a polyethylene glycol (PEG) molecule and is given as part of chemotherapy regimens that are associated with significant myelosuppression and risk for febrile neutropenia. Prescribing information available on manufacturer's website for the drug warns us about possible severe sickle cell crises related to the medication but does not report the actual incidence or the use in patients with sickle cell trait. Caution is advised when using it in patients with sickle cell disease. Here we present a case of a Caucasian female with known sickle cell trait (SCT) with no prior complications who developed a presumed sickle cell crisis after getting Neulasta, as a part of the chemotherapy regimen used to treat her breast cancer. Based on our literature review, this appears to be the first case report of a patient with SCT developing a sickle cell crisis with the pegylated form of recombinant filgrastim. Given the dearth of literature regarding the use of G-CSF and its related pegylated forms in patients with sickle cell anemia and sickle cell trait, a discussion of potential mechanisms and review of current literature and guidelines is also presented.

show abstract

Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease

Cited by 13 publications

References 12 publications

Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease

Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia

Contact Info

Product

Resources

About